United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The average investor likely doesn’t have much to do with the COVID-19 vaccine, other than eagerly awaiting its arrival so life can return to some semblance of normal. However, the average investor can partake in Pfizer’s stock – but should you?

Pfizer Attempts To Inject Optimism Into Stock With COVID-19 Vaccine

AstraZeneca

BioNTech SE

Moderna

You'll have a much better shot at getting a shot next year.

3 Reasons Why You Probably Won't Receive a Coronavirus Vaccine Shot by the End of 2020

The billionaire philanthropist thinks one company could have a coronavirus vaccine ready by November.

Here's the Company That Bill Gates Thinks Is the Clear Coronavirus Vaccine Leader

Pfizer Inc.'s (NYSE:PFE) quest for an effective Covid-19 vaccine is front and center in the news—rightfully so considering the urgent health care solutions needed due to the pandemic.

Pfizer Vaccine Business Much More Than Covid-19

Gilead Sciences

Want to invest in coronavirus vaccine stocks but are worried about their risks? This portfolio has you covered.

This 3-Stock Portfolio Is a Safe Bet on a Coronavirus Vaccine

Pfizer Inc (NYSE: PFE) on Tuesday said only mild-to-moderate side effects were observed in volunteers administered with its COVID-19 vaccine in late-stage human trials.

Pfizer Says COVID-19 Vaccine Only Showed Moderate Side-Effects In Initial Late-Stage Trials

NEW YORK--(BUSINESS WIRE)--As part of a two-day virtual Investor Day, Pfizer Inc. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE.

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

Pfizer stock kicked off the week with a big bang and coronavirus vaccine hopes. Here is how to profit from PFE right here.

Profit From Pfizer Stock as It Surges on Big Vaccine Hopes

Bristol-Myers

CytoDyn Inc.

Immunomedics

Inovio Pharmaceuticals

Mesoblast

Novavax

Sorrento Therapeutics Inc

Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles

Bill Gates says Pfizer has the best chance of seeking emergency approval for a coronavirus vaccine by next month even though he thinks such an aggressive timeline is unlikely. “The only vaccine that if everything went perfectly, might seek the emergency use license by the end of October, would be Pfizer,” the billionaire tech tycoon-turned-philanthropist.

Bill Gates says Pfizer has best shot at early COVID-19 vaccine

Our indicative theme of Coronavirus Vaccine stocks - which includes a diverse set of U.S. based pharma and biotech companies that are working on novel Coronavirus vaccines - is up by over 600% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 3%.

Moderna, Novavax, Pfizer: Coronavirus Vaccine Stocks Poised To Recover From Recent Sell Off?

Apple

Atara Biotherapeutics

American Express

Fiverr

Home Depot

Johnson & Johnson

JPMorgan Chase & Co

Coca-Cola

Merck

NIKE

Walmart

Week 38 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

On Friday the 11th the Nasdaq (QQQ) and Russell 2000 (IWM) both closed under the 50-day moving average. They were not followed by their friends the Dow Jones Industrials (DIA) and S&P 500 (SPY).

Pfizer Vaccine News Gives Stock Market Hope

Eli Lilly

Major coronavirus treatments and vaccine maker executives were interviewed on CNBC Monday to discuss their company's progress in the battle against the disease.

Gilead, Pfizer, Eli Lilly CEOs On COVID-19 Treatments, Vaccine Development

The drugmaker's CEO said there was a more than 60% chance that they would know by the end of next month if BNT162b2 is effective.

Pfizer Says It Could Know If Its COVID-19 Vaccine Candidate Works in October

Bank of America

Chevron

DTE Energy

Realty Income Corp

Buy These 5 Unknown Dividend Stocks With Yields Up To 10.8%

Pfizer (PFE) and its partner, BioNTech, are seeking FDA's approval to increase enrollment target in the late-stage study on their coronavirus vaccine candidate to diversify patient population.

Pfizer Seeks to Raise Coronavirus Study Enrollment Target

Covid-19 vaccine stocks rose after AstraZeneca resumed final-phase trials in the U.K. after a six-day pause, and Pfizer and BioNTech said they filed to expand their final-phase testing.

Covid Roundup: Pfizer Widens Test; AstraZeneca Resumes Late-Stage Trial

Pfizer stock and partner BioNTech are rallying Monday morning on news the two companies could vaccinate Americans before the end of 2020. 
The post Pfizer Stock Pops on Vaccine Timeline News, Trial Expansion appeared first on InvestorPlace.

Pfizer Stock Pops on Vaccine Timeline News, Trial Expansion

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will host its virtual Investor Day today and tomorrow: Monday, September 14, 2020 from 1:00 p.m.

Pfizer Hosts Virtual Investor Day

Pharmaceutical giant Pfizer will likely know by the end of next month if its coronavirus vaccine is effective, CEO Albert Bourla said.

Pfizer says it should know if COVID-19 vaccine works by end of October

Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Saturday they are seeking the United States Food and Drug Administration approval to expand the late-stage clinical trial of their COVID-19 vaccine, by significantly upping the number of participants and increasing their diversity.

Pfizer Seeks FDA Nod To Expand Late-Stage COVID-19 Vaccine Trial

The expansion shouldn't affect the initial data readout.

Pfizer and BioNTech Plan to Increase Size of Their Coronavirus Vaccine Clinical Trial

If the Food and Drug Administration approves the vaccine, the company is prepared to distribute "hundreds of thousands of doses, Pfizer CEO Albert Bourla said.

News for Pfizer Stock (PFE)